Magle Group successfully places senior secured bonds of SEK 350 million
24 juni, 17:20
Magle Chemoswed Holding AB (publ) ("Magle Group") has today successfully placed senior secured bonds in an amount of SEK 350 million with a tenor of three years (the "Bonds"). The Bonds will carry floating rate interest of STIBOR 3m plus 6.50 per cent. per annum and will be issued at 97 per cent. of par value. The issue date for the Bonds is expected to be on or about 4 July 2025.
The net proceeds from the Bonds will be used to refinance existing debt and for general corporate purposes, including investments, acquisitions and capital expenditure.
The Bonds will be listed on a regulated market within twelve months and Nasdaq Transfer Market within 60 days (with the intention to list within 30 days).
Pareto Securities acted as Sole Bookrunner, Advokatfirman Schjødt acted as legal advisor to Magle Group, and Roschier Advokatbyrå acted as legal advisor to Pareto Securities in connection with the bond issue. Vator Securities acted as financial advisor to Magle Group.
Contacts Justin & Aaron
Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com
Aaron Wong, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com
About Us
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.comand www.maglepharmacept.comand www.maglebiopolymers.com
Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.
This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-24 17:20 CEST.
Attachments
Magle Group successfully places senior secured bonds of SEK 350 million
Ämnen i artikeln
Magle Group successfully places senior secured bonds of SEK 350 million
24 juni, 17:20
Magle Chemoswed Holding AB (publ) ("Magle Group") has today successfully placed senior secured bonds in an amount of SEK 350 million with a tenor of three years (the "Bonds"). The Bonds will carry floating rate interest of STIBOR 3m plus 6.50 per cent. per annum and will be issued at 97 per cent. of par value. The issue date for the Bonds is expected to be on or about 4 July 2025.
The net proceeds from the Bonds will be used to refinance existing debt and for general corporate purposes, including investments, acquisitions and capital expenditure.
The Bonds will be listed on a regulated market within twelve months and Nasdaq Transfer Market within 60 days (with the intention to list within 30 days).
Pareto Securities acted as Sole Bookrunner, Advokatfirman Schjødt acted as legal advisor to Magle Group, and Roschier Advokatbyrå acted as legal advisor to Pareto Securities in connection with the bond issue. Vator Securities acted as financial advisor to Magle Group.
Contacts Justin & Aaron
Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com
Aaron Wong, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com
About Us
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.comand www.maglepharmacept.comand www.maglebiopolymers.com
Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.
This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-24 17:20 CEST.
Attachments
Magle Group successfully places senior secured bonds of SEK 350 million
Ämnen i artikeln
-992x558.webp&w=3840&q=75)
Aktierekommendationer
Analyser
-160x160.jpg&w=3840&q=75)
Oljepriset
-992x558.png&w=3840&q=75)
.jpg&w=3840&q=75)
Aktierekommendationer
Analyser
Oljepriset
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
